Empowered Funds LLC Takes $28.73 Million Position in Danaher Corporation $DHR

Empowered Funds LLC bought a new position in shares of Danaher Corporation (NYSE:DHR) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 39,911 shares of the conglomerate’s stock, valued at approximately $28,733,000.

Other hedge funds also recently added to or reduced their stakes in the company. EP Wealth Advisors LLC purchased a new position in Danaher in the 2nd quarter worth $3,807,000. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Danaher by 303.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate’s stock valued at $56,777,000 after purchasing an additional 186,584 shares during the period. Puzo Michael J acquired a new position in shares of Danaher in the second quarter valued at about $8,624,000. Legal & General Group Plc lifted its holdings in shares of Danaher by 1.0% during the fourth quarter. Legal & General Group Plc now owns 4,495,287 shares of the conglomerate’s stock worth $1,029,061,000 after purchasing an additional 43,169 shares during the period. Finally, Madison Asset Management LLC purchased a new stake in Danaher in the second quarter valued at approximately $85,451,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Up 0.2%

DHR stock opened at $215.74 on Friday. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The firm’s fifty day moving average is $198.69 and its 200 day moving average is $192.35. The firm has a market cap of $151.67 billion, a PE ratio of 38.32, a P/E/G ratio of 2.68 and a beta of 0.78.

Danaher (NYSE:DHR) last posted its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the prior year, the company posted $0.77 EPS. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, research analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.

Analyst Ratings Changes

DHR has been the subject of several research reports. DZ Bank began coverage on shares of Danaher in a research note on Wednesday, June 3rd. They set a “buy” rating and a $210.00 price objective for the company. Evercore reaffirmed an “outperform” rating and issued a $230.00 price target on shares of Danaher in a report on Monday, July 6th. Stifel Nicolaus reduced their price objective on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $240.00 price objective on shares of Danaher in a report on Wednesday, July 22nd. Finally, Piper Sandler initiated coverage on Danaher in a research note on Thursday, June 11th. They issued a “neutral” rating and a $200.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $228.91.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.